Is this report on the Range website just to upset the long term shareholder's?Nice one Finnies as of March 2006 recommended 12 month target share $0.12 or $2.40 today
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%